Browse

Experts explain how ctDNA tracking in metastatic cancer helps tailor immunotherapy, spot relapse early, and guide dose breaks—plus key limitations.

Experts weigh PLGG treatment choices, balancing chemo and MEK inhibitors, guided by vision decline, symptoms, tumor growth, and family logistics.

In this segment, Dr. Elizabeth Plimack leads a discussion with Dr. Sundhar Ramalingam and Dr. Yasser Ged on how clinicians approach treatment selection in renal cell carcinoma across different IMDC…